focus -WSS

focus

author：entertainment 2025-10-02 20:06:24 - browse：43752

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： California Joshua trees severely burned in massive wildfire

WSS

Teladoc has a new CEO, but challenges remain the same

How faith leaders like me can help address America's obesity epidemic

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Coercive sterilizations revealed by STAT prompt outrage

ALS patient reclaims some autonomy thanks to wearable 'robot'

hotspot

focus

explore

As demand for Covid shots wanes, Moderna seeks its next success

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

How to save PrEP access — and even expand it

Cigna wins case to block Amy Bricker's move to CVS

Apple is now the first public company to be valued at $3 trillion

Lilly's Alzheimer's drug donanemab backed by FDA advisers

The high cost of giving birth even with insurance

Teladoc has a new CEO, but challenges remain the same

In age of alternative facts, a scholarly course on calling out crap

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Wikipedia

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Readers discuss the intersection of pregnancy and addiction

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Climate activists disrupt London Pride march to protest corporate sponsorship

Lifetime voting ban for felony convictions struck down in Mississippi

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

focus

leisure time

entertainment

focus